Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $65.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price hoisted by equities research analysts at Oppenheimer from $63.00 to $65.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price target would suggest a potential upside of 39.77% from the company’s previous close.

Separately, William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $52.00.

Tarsus Pharmaceuticals Trading Down 2.2 %

Shares of NASDAQ TARS opened at $46.51 on Thursday. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. The business has a fifty day simple moving average of $37.17 and a two-hundred day simple moving average of $32.33. The firm has a market cap of $1.77 billion, a PE ratio of -10.38 and a beta of 1.00. Tarsus Pharmaceuticals has a twelve month low of $15.60 and a twelve month high of $51.59.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Cowen AND Company LLC raised its position in shares of Tarsus Pharmaceuticals by 3.5% in the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock worth $59,725,000 after acquiring an additional 74,855 shares in the last quarter. Jennison Associates LLC raised its position in shares of Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after acquiring an additional 698,712 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Tarsus Pharmaceuticals by 14.5% in the 1st quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after acquiring an additional 231,131 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Tarsus Pharmaceuticals by 7.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after acquiring an additional 77,825 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in Tarsus Pharmaceuticals by 1,113.5% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock valued at $32,642,000 after buying an additional 824,000 shares in the last quarter. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.